Market Overview:
The global cefuroxime sodium API market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for cefuroxime sodium API in various applications such as cefuroxime sodium injection and oral formulations. In addition, the growing prevalence of infectious diseases is also contributing to the growth of this market. On the basis of type, the global cefuroxime sodium API market can be segmented into purity ≥ 98 % and purity ≥ 99 % segments. The purity ≥ 98 % segment is expected to account for a larger share of this market than the purity ≥ 99 % segment during the forecast period from 2018 to 2030. This can be attributed to its lower price point as compared with that of other types of cefuroxime sodium APIs available in the market. On the basis of application,the global cefuroxime sodium APImarket can be divided into two segments:cEFUROXIME SODIUM INJECTION and CEFUROXIME SODIUM ORAL FORMULATIONS .
Product Definition:
Cefuroxime Sodium API is a cephalosporin antibiotic that is used to treat a variety of infections. It works by killing the bacteria that are causing the infection.
Purity ≥ 98 %:
Cefuroxime sodium is an antibiotic drug, which is widely used for the treatment of bacterial infections. It works by killing the bacteria that causes infection. The drug has a wide application in skin diseases caused by acne and staphylococcus infections. Increasing prevalence of such skin diseases due to unhealthy lifestyle and eating habits are expected to drive market growth over the forecast period.
Purity ≥ 99 %:
Cefuroxime sodium is a cephalosporin antibiotic drug and it's used to treat bacterial infections of the skin, respiratory tract, and female reproductive system. The drug has no serious side effects but may cause mild symptoms such as diarrhea, stomach pain or cramps, nausea or vomiting. These symptoms usually go away after a few days.
Application Insights:
Cefuroxime sodium injection accounted for the largest revenue share of over 70.0% in 2017 and is anticipated to maintain its dominance over the forecast period. The product is used for the treatment of bacterial infections, such as respiratory tract infections, skin & skin structure infection, urinary tract infections and ear infection among others. Bacterial diseases that are commonly found in humans include tuberculosis, salmonella poisoning and streptococcus among others.
The oral cefuroxime products are expected to witness significant growth with a CAGR of XX%, in terms of revenue during the forecast period owing to increasing awareness about antibiotic alternatives by healthcare professionals coupled with rising consumer preference for self-medication due to high costs associated with medical consultation visits and prescription drugs globally.
Regional Analysis:
North America dominated the global market in 2017. This is attributed to the presence of a large number of healthcare facilities, increasing incidence of multi-drug resistant tuberculosis and high adoption rate for new technologies. Moreover, growing initiatives by government bodies to raise awareness regarding MDR and XDR tuberculosis are expected to propel product demand over the forecast period.
Asia Pacific is anticipated to witness significant growth over the coming years owing to rising healthcare expenditure, improving economic conditions and an increase in investments for new drug development programs against TB.
The European market was valued at USD X billion in 2017 owing to high prevalence rates of multidrug-resistant tuberculosis coupled with stringent government regulations pertaining quality standards for medicines used against infectious diseases such as TB The region’s largest markets were Germany (USD X million) followed by France (USD X million).
Growth Factors:
- Increasing prevalence of infectious diseases: The global incidence of infectious diseases is increasing every year, which is expected to drive the demand for cefuroxime sodium API in the coming years.
- Rising demand for cephalosporins: Cephalosporins are a class of antibiotics that are widely used to treat various types of infections. The growing demand for cephalosporins is expected to boost the market for cefuroxime sodium API in the near future.
- Technological advancements in drug development: The pharmaceutical industry is witnessing rapid advancements in drug development technologies, which is likely to fuel the growth of the cefuroxime sodium API market in the coming years.
- Growing awareness about antibiotic resistance: There has been a significant increase in awareness about antibiotic resistance among people across the globe, which is likely to propelthe growth ofthecafuroximesodiumAPImarketin themid-to-long term future . 5 Increased funding for R&D activities: Pharmaceutical companies are investing heavily intoresearch anddevelopmentactivitiesfornewantibioticsandcefuroximesodiumAPIisexpectedtobecomeoneoftheleadingproductsinthefuture
Scope Of The Report
Report Attributes
Report Details
Report Title
Cefuroxime Sodium API Market Research Report
By Type
Purity ≥ 98 %, Purity ≥ 99 %
By Application
Cefuroxime Sodium Injection, Cefuroxime Sodium Oral
By Companies
ACS Dobfar, Sterile India, Nectar Lifesciences, Hangzhou Viwa, Sinopharm Weiqida Pharmaceutical, Virchow Healthcare, United Laboratories International Holdings, Titan Pharmaceutical, Guangzhou Pi & Pi Biotech, Fresenius Kabi iPSUM, ACS Dobfar
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Cefuroxime Sodium API Market Report Segments:
The global Cefuroxime Sodium API market is segmented on the basis of:
Types
Purity ≥ 98 %, Purity ≥ 99 %
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cefuroxime Sodium Injection, Cefuroxime Sodium Oral
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ACS Dobfar
- Sterile India
- Nectar Lifesciences
- Hangzhou Viwa
- Sinopharm Weiqida Pharmaceutical
- Virchow Healthcare
- United Laboratories International Holdings
- Titan Pharmaceutical
- Guangzhou Pi & Pi Biotech
- Fresenius Kabi iPSUM
- ACS Dobfar
Highlights of The Cefuroxime Sodium API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity ≥ 98 %
- Purity ≥ 99 %
- By Application:
- Cefuroxime Sodium Injection
- Cefuroxime Sodium Oral
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cefuroxime Sodium API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cefuroxime sodium API is a cephalosporin antibiotic. It is used to treat infections caused by bacteria, such as pneumonia, bronchitis, and urinary tract infections.
Some of the major companies in the cefuroxime sodium api market are ACS Dobfar, Sterile India, Nectar Lifesciences, Hangzhou Viwa, Sinopharm Weiqida Pharmaceutical, Virchow Healthcare, United Laboratories International Holdings, Titan Pharmaceutical, Guangzhou Pi & Pi Biotech, Fresenius Kabi iPSUM, ACS Dobfar.
The cefuroxime sodium api market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cefuroxime Sodium API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cefuroxime Sodium API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cefuroxime Sodium API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cefuroxime Sodium API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cefuroxime Sodium API Market Size & Forecast, 2018-2028
4.5.1 Cefuroxime Sodium API Market Size and Y-o-Y Growth
4.5.2 Cefuroxime Sodium API Market Absolute $ Opportunity
Chapter 5 Global Cefuroxime Sodium API Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cefuroxime Sodium API Market Size Forecast by Type
5.2.1 Purity ≥ 98 %
5.2.2 Purity ≥ 99 %
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cefuroxime Sodium API Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cefuroxime Sodium API Market Size Forecast by Applications
6.2.1 Cefuroxime Sodium Injection
6.2.2 Cefuroxime Sodium Oral
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cefuroxime Sodium API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cefuroxime Sodium API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cefuroxime Sodium API Analysis and Forecast
9.1 Introduction
9.2 North America Cefuroxime Sodium API Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cefuroxime Sodium API Market Size Forecast by Type
9.6.1 Purity ≥ 98 %
9.6.2 Purity ≥ 99 %
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cefuroxime Sodium API Market Size Forecast by Applications
9.10.1 Cefuroxime Sodium Injection
9.10.2 Cefuroxime Sodium Oral
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cefuroxime Sodium API Analysis and Forecast
10.1 Introduction
10.2 Europe Cefuroxime Sodium API Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cefuroxime Sodium API Market Size Forecast by Type
10.6.1 Purity ≥ 98 %
10.6.2 Purity ≥ 99 %
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cefuroxime Sodium API Market Size Forecast by Applications
10.10.1 Cefuroxime Sodium Injection
10.10.2 Cefuroxime Sodium Oral
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cefuroxime Sodium API Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cefuroxime Sodium API Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cefuroxime Sodium API Market Size Forecast by Type
11.6.1 Purity ≥ 98 %
11.6.2 Purity ≥ 99 %
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cefuroxime Sodium API Market Size Forecast by Applications
11.10.1 Cefuroxime Sodium Injection
11.10.2 Cefuroxime Sodium Oral
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cefuroxime Sodium API Analysis and Forecast
12.1 Introduction
12.2 Latin America Cefuroxime Sodium API Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cefuroxime Sodium API Market Size Forecast by Type
12.6.1 Purity ≥ 98 %
12.6.2 Purity ≥ 99 %
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cefuroxime Sodium API Market Size Forecast by Applications
12.10.1 Cefuroxime Sodium Injection
12.10.2 Cefuroxime Sodium Oral
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cefuroxime Sodium API Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cefuroxime Sodium API Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cefuroxime Sodium API Market Size Forecast by Type
13.6.1 Purity ≥ 98 %
13.6.2 Purity ≥ 99 %
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cefuroxime Sodium API Market Size Forecast by Applications
13.10.1 Cefuroxime Sodium Injection
13.10.2 Cefuroxime Sodium Oral
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cefuroxime Sodium API Market: Competitive Dashboard
14.2 Global Cefuroxime Sodium API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 ACS Dobfar
14.3.2 Sterile India
14.3.3 Nectar Lifesciences
14.3.4 Hangzhou Viwa
14.3.5 Sinopharm Weiqida Pharmaceutical
14.3.6 Virchow Healthcare
14.3.7 United Laboratories International Holdings
14.3.8 Titan Pharmaceutical
14.3.9 Guangzhou Pi & Pi Biotech
14.3.10 Fresenius Kabi iPSUM
14.3.11 ACS Dobfar
